(79) constructed targeting CD19 IL-12-CAR-T cells in a preclinical study on the treatment of lymphoma, and the CAR-T cells expressing IL-12 in the trial not only killed CD19+ tumor cells directly, but also recruited other immune cells of the host for anti-tumor immune response. This evidence concerns the gene CD19 and lymphoma.